RxDoctor Payments Data

Helen Stockinger, MD

Internal Medicine · Spartanburg, SCNPI 1801851290

Payments from drug & device makers

$6,107in general payments, 2019–2025

Across 366 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$822
  • AstraZeneca$353
  • Sumitomo Pharma America, Inc.$308
  • Neurocrine Biosciences, Inc.$275
  • Amgen$269
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,107 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$272,121
Medicare patients
628
Services billed
4,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$264,579
OzempicSemaglutide223$216,352
FarxigaDapagliflozin Propanediol161$138,336
JardianceEmpagliflozin122$130,200
Repatha SureclickEvolocumab154$104,778
XareltoRivaroxaban102$98,800
MounjaroTirzepatide71$72,063
LinzessLinaclotide70$60,289
MyrbetriqMirabegron92$55,231
JanuviaSitagliptin Phosphate83$52,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$34,819
TrulicityDulaglutide27$32,132
ViberziEluxadoline21$31,911
EntrestoSacubitril/Valsartan25$22,105
RybelsusSemaglutide20$19,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica, Premarin$822$283,979315 claims
Novo NordiskOzempic, Rybelsus$225$236,062243 claims
AstraZenecaFarxiga, Breztri Aerosphere$353$145,791173 claims
Boehringer IngelheimJardiance, Combivent Respimat$164$135,790134 claims
AbbVieLinzess, Viberzi, Qulipta$1,113$108,323107 claims
Lilly USA, LLCMounjaro, Trulicity$249$104,19598 claims
Johnson & JohnsonXarelto$41$98,800102 claims
MerckJanuvia, Janumet Xr$77$67,053100 claims
Astellas Pharma US IncMyrbetriq$150$55,23192 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$140$49,76679 claims
NovartisEntresto$252$22,10525 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$18,34314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →